Overall rank by patents
#37,476
Across all tracked assignees
USPTO PatentsView assignee record - 7 granted patents across 6 technology areas, active 2023–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: H04N (PICTORIAL COMMUNICATION, e.g. TELEVISION).
The verdict
SR holds 7 US patents across 6 technology areas, rank #37,476 of 50,000 tracked assignees.
SR LABS, Inc. has been granted 7 US utility patents between 2023 and 2025, placing SR LABS, Inc. at rank #37,476 across all assignees tracked by PlainPatent. This portfolio spans 6 distinct Cooperative Patent Classification (CPC) subclasses, averaging 15.9 claims per patent with primary concentration in H04N (PICTORIAL COMMUNICATION, e.g. TELEVISION). As a US Corporation, SR LABS, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, SR sits between Spero Therapeutics, Inc. (7 patents, rank #37,472) and ST&T International, Inc. (7 patents, rank #37,480) - the closest US assignees by grant volume. The composite Innovation Score of 45.4/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2023 through 2025, with 7 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. SR LABS, Inc.'s 15.9 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 6 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark SR LABS, Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
SPERO THERAPEUTICS, INC.
7 patents
SPINETHERA
7 patents
SPIRE GLOBAL SUBSIDIARY, INC.
7 patents
SPRING LOADED TECHNOLOGY INCORPORATED
7 patents
SRC INNOVATIONS, LLC
7 patents
SRG Global Liria, S.L.
7 patents
SSM Schärer Schweiter Mettler AG
7 patents
ST&T INTERNATIONAL, INC.
7 patents
SR LABS, INC.
7 patents
What this shows SR holds 7 patents at rank #37,476, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #37,476 in granted patent volume.
Other assignees with the most granted patents in SR's primary technology class.
SR's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
45 Top 23% higher than 77% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2023–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2023 | 3 | 42.9% |
| 2024 | 2 | 28.6% |
| 2025 | 2 | 28.6% |
Top 6 of 6 technology areas
Overall rank by patents
#37,476
Across all tracked assignees
45.4 out of 100
How to use this portfolio
SR's 7 grants land it in the top 23% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.